446 related articles for article (PubMed ID: 35306339)
21. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
Qin L; Saumu MT; Wang H; Shi H; Hu X; Cheng P
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):348-50, 370. PubMed ID: 16201293
[TBL] [Abstract][Full Text] [Related]
22. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.
Zhu BH; Lv HT; Sun L; Zhang JM; Cao L; Jia HL; Yan WH; Shen YP
Eur J Pediatr; 2012 Mar; 171(3):571-8. PubMed ID: 22057683
[TBL] [Abstract][Full Text] [Related]
23. Infliximab as a second-line therapy for children with refractory Kawasaki disease: A systematic review and meta-analysis of randomized controlled trials.
Kabbaha S; Milano A; Aldeyab MA; Thorlund K
Br J Clin Pharmacol; 2023 Jan; 89(1):49-60. PubMed ID: 36169097
[TBL] [Abstract][Full Text] [Related]
24. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[TBL] [Abstract][Full Text] [Related]
25. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
26. Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.
Zheng X; Li J; Yue P; Liu L; Li J; Zhou K; Hua Y; Li Y
PLoS One; 2021; 16(3):e0248812. PubMed ID: 33764989
[TBL] [Abstract][Full Text] [Related]
27. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
28. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH
Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
[TBL] [Abstract][Full Text] [Related]
29. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
[TBL] [Abstract][Full Text] [Related]
30. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
Crayne CB; Mitchell C; Beukelman T
Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898
[TBL] [Abstract][Full Text] [Related]
31. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
Platt B; Belarski E; Manaloor J; Ofner S; Carroll AE; John CC; Wood JB
JAMA Netw Open; 2020 Jan; 3(1):e1918565. PubMed ID: 31899532
[TBL] [Abstract][Full Text] [Related]
33. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
Hashino K; Ishii M; Iemura M; Akagi T; Kato H
Pediatr Int; 2001 Jun; 43(3):211-7. PubMed ID: 11380911
[TBL] [Abstract][Full Text] [Related]
34. Association of Genetic Polymorphisms in Kawasaki Disease with the Response to Intravenous Immunoglobulin Therapy.
Sapountzi E; Fidani L; Giannopoulos A; Galli-Tsinopoulou A
Pediatr Cardiol; 2023 Jan; 44(1):1-12. PubMed ID: 35908117
[TBL] [Abstract][Full Text] [Related]
35. Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study.
Inamo Y; Saito K; Hasegawa M; Hayashi R; Nakamura T; Abe O; Ishikawa T; Yoshino Y; Hashimoto K; Fuchigami T
BMC Pediatr; 2014 Jan; 14():27. PubMed ID: 24479564
[TBL] [Abstract][Full Text] [Related]
36. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
Wang J; Chen H; Shi H; Zhang X; Shao Y; Hang B; Xu Z; Rong X; Chu M; Qiu H
Pediatr Rheumatol Online J; 2020 Jun; 18(1):48. PubMed ID: 32527316
[TBL] [Abstract][Full Text] [Related]
37. Management of acute and refractory Kawasaki disease.
Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
[TBL] [Abstract][Full Text] [Related]
38. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
39. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease.
Michihata N; Suzuki T; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
Eur J Pediatr; 2022 Oct; 181(10):3607-3615. PubMed ID: 35925450
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
Hu JW; Zhou ZS; Yang L; Zheng CN; Wang KD
Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1259-64. PubMed ID: 21756798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
